A Glycovariant of Human CD44 is Characteristically Expressed on Human Mesenchymal Stem Cells

A bstract The clinical effectiveness of systemically administered human mesenchymal stem cells (hMSCs) depends on their capacity to engage vascular endothelium. hMSCs derived from bone marrow (BM‐hMSCs) natively lack endothelial binding capacity, but express a CD44 glycovariant containing N‐linked sialyllactosamines that can be α(1,3)‐fucosylated using fucosyltransferase‐VI (FTVI) to enforce sLe X decorations, thereby creating hematopoietic cell E‐/L‐selectin ligand (HCELL). HCELL expression programs potent shear‐resistant adhesion of circulating cells to endothelial beds expressing E‐selectin. An alternative source of hMSCs is adipose tissue (A‐hMSCs), and we assessed whether A‐hMSCs bind E‐selectin and/or possess sialyllactosamine‐decorated CD44 accessible to α(1,3)‐fucosylation. Similar to BM‐hMSCs, we found that A‐hMSCs natively lack E‐selectin ligands, but FTVI‐mediated cell surface α(1,3)‐fucosylation induces sLe X expression and robust E‐selectin binding secondary to conversion of CD44 into HCELL. Moreover, treatment with the α(1,3)‐fucosyltransferase‐FTVII also generated expression of HCELL on both BM‐hMSCs and A‐hMSCs, with sLe X decorations created on N‐linked glycans of the “standard” CD44 (CD44s) isoform. The finding that hMSCs from both source tissues each lack native E‐selectin ligand expression prompted examination of the expression of glycosyltransferases that direct lactosaminyl glycan synthesis. These studies reveal that both types of hMSCs conspicuously lack transcripts encoding α(1,3)‐fucosyltransferases, but equally express glycosyltransferases critical to creation of sialyllactosamines. Collectively, these data indicate that assembly of a sialyllactosaminyl‐decorated CD44s glycovariant is a conserved feature of hMSCs derived from adipose tissue and marrow, thus identifying a CD44 glycosignature of these cells and supporting the applicability of cell surface α(1,3)‐fucosylation in programming migration of systemically administered A‐hMSCs to sites of tissue injury/inflammation. S tem C ells 2017;35:1080–1092